Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary ...
Northrop Grumman Corporation NOC is scheduled to report third-quarter 2025 results on Oct. 21, before market open. The ...
Lockheed Martin Corporation LMT is scheduled to release third-quarter 2025 results on Oct. 21, before market open. The ...
Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary ...
The ABE 1.01 is ready for use in surveillance operations, however, the aim is to eventually use it for lethal capabilities, ...